Abstract Details
|
Steve Kanes, MD, PhD
(Sage Therapeutics)
PRESENTER |
Dr. Kanes has received personal compensation for serving as an employee of Sage Therapeutics. Dr. Kanes has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Verge Genomics. Dr. Kanes has received intellectual property interests from a discovery or technology relating to health care. |
| Eric Rosenthal, MD (Massachusetts General Hospital) | Dr. Rosenthal has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma, Inc. . Dr. Rosenthal has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ceribell, Inc. . The institution of Dr. Rosenthal has received research support from Sage Therapeutics. Dr. Rosenthal has received intellectual property interests from a discovery or technology relating to health care. |
| Henrikas Vaitkevicius, MD (Marinus Pharmaceuticals) | Dr. Vaitkevicius has received personal compensation for serving as an employee of Marinus Pharmaceuticals. Dr. Vaitkevicius has stock in Marinus Pharmaceuticals. |
| Jan Claassen, MD, PhD (Columbia University College of Physicians & Surgeons) | Dr. Claassen has stock in iCE Neurosystems. The institution of Dr. Claassen has received research support from NINDS. The institution of Dr. Claassen has received research support from McDonnel Foundation. Dr. Claassen has received publishing royalties from a publication relating to health care. Dr. Claassen has received publishing royalties from a publication relating to health care. |
| Mark Wainwright, MD, PhD, FAAN (Division of Neurology Seattle Childrens Hospital) | Dr. Wainwright has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sage Therapeutics. |
| Ethan Hoffman | No disclosure on file |
| Mollie Baird | No disclosure on file |
| No disclosure on file | |
| Helen Colquhoun | Helen Colquhoun has received personal compensation for serving as an employee of Sage Therapeutics. Helen Colquhoun has stock in Sage Therapeutics. Helen Colquhoun has received intellectual property interests from a discovery or technology relating to health care. |